Eli Lilly Retatrutide: Phase 3 Obesity Trial Success Eli Lilly's retatrutide met primary endpoint. Patients achieved significant weight loss. Drug showed roughly 25% body weight reduction. This reinforces Lilly's metabolic disease lead. Eli Lilly announced positive Phase 3 results for retatrutide in obesity. The trial successfully met its primary endpoint, demonstrating substantial weight loss. Patients treated with retatrutide experienced an average reduction of approximately one-quarter of their total body weight. This outcome positions retatrutide as a highly efficacious candidate in the competitive obesity treatment landscape. This Phase 3 success triggers immediate regulatory submission preparations. Eli Lilly will compile data for New Drug Application (NDA) submission to the FDA and Marketing Authorization Application (MAA) to the EMA. The FDA's 21 CFR Part 314 outlines the requirements for NDA submissions. EMA's centralized procedure will govern its review. Expect priority review designation given the significant unmet medical need in obesity. Retatrutide's strong efficacy further solidifies Eli Lilly's dominance in metabolic disorders. It sets a new, high benchmark for competitors like Novo Nordisk's Wegovy and Amgen's AMG 133. This result could reshape market share dynamics. Eli Lilly anticipates filing for regulatory approval by late 2026.